NovaBridge Biosciences (NBP) Piper Sandler 36th Annual Healthcare Conference summary

Company overview and strategic changes

• Recently transitioned to a U.S.-focused company after divesting China assets, reducing headcount from 200 to 33 and focusing on three clinical-stage IO oncology assets.

• Emphasizes efficiency and leveraging a strong financial position to advance the pipeline and create value for investors and patients.

• Open to business development opportunities, both out-licensing and in-licensing, with a focus on finding the right partners for late-stage clinical development.

• Recent validation through a deal with Sanofi for greater China rights to UliledlIMab, with significant upfront and total deal value.

Givastomig (Giva) clinical development and differentiation

• Giva activates T cells via the 4-1BB pathway only in Claudin 18.2-positive tumor environments, reducing systemic toxicity and showing strong efficacy in gastric cancer.

• Demonstrates a favorable safety profile with no dose-limiting toxicities and lower GI-related adverse events compared to competitors like Zolbi.

• Shows potential for broader application beyond gastric cancer, including pancreatic and other GI cancers.

• Clinical trials cast a wide net for Claudin 18.2 expression, with responses seen even at low expression levels, potentially filling gaps left by competitors.

• Ongoing dose escalation studies in combination with Nivolumab and chemotherapy, with data expected in the second half of 2025.

UliledlIMab (Uli) and adenosine pathway strategy

• Uli is a CD73 antibody that fully blocks CD73 activity without the hook effect, showing strong proof of concept in lung cancer.

• Ongoing studies in China and the U.S. will inform optimal dosing and support progression to phase III trials, with key data readouts expected in 2025.

• Strategic focus is on combining Uli with chemo and PD-1 inhibitors, leveraging chemotherapy-induced CD73 expression to maximize efficacy.

• Patient selection based on CD73 expression is expected to enhance outcomes, with retrospective biomarker analysis planned.